Clinical trials: Cardiovascular Disease Acute
Heart Failure, Congestive
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
- Trial name
- RELAX-AHF (NCT00520806)
- Testing
- Relaxin
- Where
- 3 sites in United States, Israel
- Volunteers
- 1,161 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Acute Ischemic Stroke
Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Stroke Patients
A Feasibility Study to evaluate the initial safety and performance of the RapidPulseTM Aspiration System in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO).
- Trial name
- RapidPulseFS (NCT05122637)
- Testing
- RapidPulseTM Aspiration System, Standard of Care Aspiration Thrombectomy System
- Where
- 5 sites in Brazil, Denmark and 3 more
- Volunteers
- 80 people
- Sponsor
- RapidPulse, Inc
Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs)
MBA Early Feasibility Study
The MBA 25-04 study is a prospective, multicenter, non-randomized, single-arm, early feasibility study designed to assess the initial safety of the MBA device through five years following the index endovascular procedure.
- Conditions
- Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs), Thoracic Aortic Dissection, Pseudoaneurysm
- Trial name
- NCT07564375
- Testing
- GORE® Multibranch Arch Endoprosthesis, GORE® Ascending Stent Graft
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- W.L.Gore & Associates
Cerebrovascular Accident
Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients
The purpose of this study is to assess the safety and feasibility of the NeuroFlo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment.
- Trial name
- Flo 24 (NCT00436592)
- Testing
- NeuroFlo™ Catheter
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- CoAxia
Acute Coronary Syndrome
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk.
- Trial name
- CHI SQUARE (NCT01201837)
- Testing
- CER-001
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 507 people
- Sponsor
- Cerenis Therapeutics, SA
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting.
- Trial name
- NCT06095557
- Testing
- Sponsor MCG device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- SB Technology, Inc.
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.
- Conditions
- Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT02265731
- Testing
- azacitadine, venetoclax, rituximab / IDEC-C2B8
- Where
- 14 sites in Japan
- Volunteers
- 38 people
- Sponsor
- AbbVie
Thoracic Aortic Dissection
Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY（PATENCY）
A prospective, multi-centre, objective performance criteria clinical trial to evaluate the safety and efficacy of Artery Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD.
- Trial name
- NCT03767777
- Testing
- Artery Stent Graft System
- Where
- 21 sites in China
- Volunteers
- 150 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Acute Coronary Syndrome
IDE-ALERTS Continued Access Study
This Continued Access IDE Study includes a subset of former ALERTS trial (NCT00781118) patients and provides performance data for a refined Guardian implantable medical device (AMSG3-E) with a new battery designed to extend…
- Trial name
- ALERTS-CAS (NCT04316481)
- Testing
- AngelMed Guardian System
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Angel Medical Systems
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Hematological Malignancy, Leukemia
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
The purpose of this study is to determine the safety and anti-tumor effects of an experimental immunotherapy drug, called AlloStim, which is intentionally mis-matched immune cells which are designed to elicit the same anti-tumor…
- Conditions
- Hematological Malignancy, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00558675
- Testing
- AlloStim
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Mirror Biologics, Inc.
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Sudden Cardiac Arrest, Acute Myocardial Infarction
Improve SCA Bridge Study
The purpose of the Improve SCA Bridge study is to characterize the care pathway flow of post-acute myocardial infarction (MI) patients as a result of standard assessments of left ventricular ejection fraction (LVEF) in the acute…
- Trial name
- NCT03715790
- Testing
- EP referred group, Non-Referred group
- Where
- 52 sites in Bangladesh, Brunei and 14 more
- Volunteers
- 1,491 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Ischemic Stroke
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to…
- Trial name
- NCT06129175
- Testing
- Neuroncell-EX
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Cytopeutics Sdn. Bhd.
Acute Coronary Syndrome
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real…
- Trial name
- TRANSLATE-ACS (NCT01088503)
- Testing
- ADP receptor inhibitors
- Where
- 186 sites in United States, Puerto Rico
- Volunteers
- 12,227 people
- Sponsor
- Eli Lilly and Company
Acute Ischemic Stroke
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
- Trial name
- NCT00499902
- Testing
- alfimeprase
- Where
- 22 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- ARCA Biopharma, Inc.
Aortic Dissection
The VIRTUE Post Marketing Surveillance Registry
The purpose of this post-market release registry is to collect additional information concerning safety, performance and health economic data with respect to the Medtronic VALIANT Thoracic Stent Graft with the Xcelerant Delivery…
- Trial name
- VIRTUE (NCT01213589)
- Volunteers
- 100 people
- Sponsor
- Medtronic Endovascular
Acute Ischemic Stroke
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome in patients with acute ischemic stroke…
- Trial name
- NCT01790997
- Testing
- DLBS1033, Aspirin, Clopidogrel
- Where
- Indonesia
- Volunteers
- 126 people
- Sponsor
- Dexa Medica Group
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Aortic Dissection
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.
- Trial name
- ARISE III (NCT06827990)
- Testing
- GORE® Ascending Stent Graft (ASG device)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- W.L.Gore & Associates
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.